Mablytics, Inc.

Mablytics, Inc. is a preclinical-stage biotechnology company with the slogan "Innovation that delivers." The company is focused on developing immunotherapies that are precisely delivered by means of a novel target. Recent studies have demonstrated highly restricted expression of the novel target in normal tissues, but overexpression in certain cancers. This discovery has paved the way for immunotherapies directed at this target, which have the potential for highly effective treatment with low toxicity. Mablytics aims to open the door to a more potent and yet safer immunotherapy by identifying predictive biomarkers that determine the likelihood of benefit or toxicities from potential therapies. The company was founded in 2019 and operates in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. The groundbreaking work being conducted at Mablytics holds promise for a new generation of patients, as targeted therapies can be selectively delivered to tumor cells across multiple cancer types, minimizing effects on non-cancerous cells. By identifying patients at risk for having the specific protein and optimizing treatment of particular cancers across patient groups, Mablytics is at the forefront of personalized medicine in the field of cancer treatment. As a preclinical-stage company, Mablytics has not disclosed its headquarter location or specific investors or investment details at this time. However, with its pioneering approach to immunotherapy, Mablytics is poised to make a significant impact in the ongoing fight against cancer.